Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 451 to 465 of 866 results for score

  1. Sinusitis (acute): antimicrobial prescribing (NG79)

    This guideline sets out an antimicrobial prescribing strategy for acute sinusitis. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sinusitis is usually caused by a virus, lasts for about 2 to 3 weeks, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.

  2. Micropressure therapy for refractory Ménière's disease (IPG426)

    Evidence-based recommendations on micropressure therapy for refractory Ménière's disease. This involves inserting a grommet (small tube) through the eardrum into the middle ear and blowing air at low pressure into the inner ear.

  3. Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms (IPG658)

    Evidence-based recommendations on endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms in adults. This involves inserting a wire-mesh device into the aneurysm to act as a plug when a blood clot forms inside it.

  4. Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

    Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.

  5. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

  6. Coil embolisation of unruptured intracranial aneurysms (IPG105)

    Evidence-based recommendations on coil embolisation of unruptured intracranial aneurysms. This involves placing coils inside the aneurysm using a thin tube to make the blood clot so it is less likely to burst.

  7. Transperineal template biopsy and mapping of the prostate (IPG364)

    Evidence-based recommendations on transperineal template biopsy of the prostate. This involves inserting many fine needles though the skin between the scrotum and the anus in order to obtain tissue samples from the prostate for testing.

  8. Minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain (IPG578)

    Evidence-based recommendations on minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain in adults. This involves fixing the sacrum to the ilium using 2 or 3 metal implants.

  9. Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)

    Evidence-based recommendations on ibrutinib (Imbruvica) with venetoclax (Venclyxto) for untreated chronic lymphocytic leukaemia in adults.

  10. Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)

    Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.

  11. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)

    Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.

  12. Elafibranor for previously treated primary biliary cholangitis (TA1016)

    Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.

  13. Relugolix for treating hormone-sensitive prostate cancer (TA995)

    Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.

  14. Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

    Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults.

  15. Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)

    Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.